Gelteq Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GELS Nasdaq 2836 www.gelteq.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gelteq Limited

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs - Jun 17th, 2026 6:30 am
Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications - Jun 12th, 2026 10:30 am
Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion - Jun 4th, 2026 7:08 am
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway - May 20th, 2026 6:00 am
Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA - May 14th, 2026 6:35 am
Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth - May 12th, 2026 6:00 am
Q1 Virtual Investor Summit Presentations Now Available On Demand - Mar 26th, 2026 1:46 pm
Investor Summit Announces Q1 Presenter Line Up (Presentations 3/25, 1-on-1s 3/26) - Mar 20th, 2026 6:00 am
Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership - Feb 11th, 2026 6:45 am
Gelteq announces preclinical results on medicinal cannabinoid absorption - Jan 14th, 2026 7:16 am
Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq’s Nutritional Product Expansion into China - Dec 9th, 2025 7:15 am